Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Draft Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees, 77403-77405 [E5-8115]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
77403
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
collection of information to OMB for
review and clearance.
Food and Drug Administration
Food and Drug Administration
[Docket No. 2005N–0178]
[Docket No. 2001D–0489] (formerly Docket
No. 01D–0489)
Draft Guidance for Clinical Trial
Sponsors: Establishment and Operation
of Clinical Trial Data Monitoring
Committees
The draft guidance document, when
finalized, is intended to assist sponsors
of clinical trials in determining when a
Data Monitoring Committee (DMC) is
needed for study monitoring, and how
such committees should operate. The
draft guidance was revised based on
public comments. The draft guidance
addresses the roles, responsibilities, and
operating procedures of DMCs, and
describes certain reporting and
recordkeeping responsibilities including
the following: (1) Sponsor notification
to the DMC regarding waivers of
expedited reporting, (2) DMC reports of
meeting minutes to the sponsor, (3)
sponsor reporting to FDA on DMC
safety-related recommendations, (4)
standard operating procedures (SOPs)
for DMCs, (5) DMC meeting records, and
(6) DMC reports to the sponsor.
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Regulations Under the Federal Import
Milk Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Draft Guidance for
Clinical Trial Sponsors: Establishment
and Operation of Clinical Trial Data
Monitoring Committees
AGENCY:
Notice.
Food and Drug Administration,
HHS.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Regulations Under the Federal Import
Milk Act’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
In the
Federal Register of October 7, 2005 (70
FR 58709), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0212. The
approval expires on December 31, 2008.
A copy of the supporting statement for
this information collection is available
on the Internet at https://www.fda.gov/
ohrms/dockets.
SUPPLEMENTARY INFORMATION:
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5–8114 Filed 12–29–05; 8:45 am]
BILLING CODE 4160–01–S
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by January 30,
2005.
ADDRESSES: OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: Fumie Yokota, Desk Officer
for FDA, FAX: 202–395–6974.
Submit written requests for single
copies of the draft guidance dated
December 2005 to the Office of
Communication, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. Send one
self-addressed adhesive label to assist
the office in processing your requests.
The draft guidance may also be obtained
by mail by calling CBER at 1–800–835–
4709 or 301–827–1800. Persons with
access to the Internet may obtain the
draft guidance at either https://
www.fda.gov/cber/guidelines.htm or
https://www.fda.gov/ohrms/dockets/
default.htm.
wwhite on PROD1PC61 with NOTICES
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
A. Sponsor Notification to the DMC
Regarding Waivers
The sponsor has the responsibility of
reporting to FDA serious, unexpected
adverse events in drugs and biologics
trials under part 312 (21 CFR part 312)
in § 312.32 and unanticipated adverse
events in the case of device trials under
part 812 (21 CFR part 812) in
§ 812.150(b)(1). We recommend in the
draft guidance that sponsors notify
DMCs about any waivers granted by
FDA for expedited reporting of certain
serious events.
B. DMC Report of Meeting Minutes to
the Sponsor
FDA recommends in the draft
guidance that the DMC issue a written
report to the sponsor based on the
meeting minutes. Reports to the sponsor
should include only those data
generally available to the sponsor. The
sponsor may convey the relevant
information in this report to other
interested parties such as study
investigators. Meeting minutes or other
information that include discussion of
confidential data would not be provided
to the sponsor.
C. Sponsor reporting to FDA on DMC
Safety-Related Recommendations
The requirement of the sponsor to
report DMC recommendations related to
serious adverse events in an expedited
manner in clinical trials of new drugs
(§ 312.32(c)) would not apply when the
DMC recommendation is related to an
excess of events not classifiable as
E:\FR\FM\30DEN1.SGM
30DEN1
77404
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
serious. Nevertheless, we recommend in
the draft guidance that sponsors inform
FDA about all recommendations related
to the safety of the investigational
product whether or not the adverse
event in question meets the definition of
‘‘serious.’’
D. Standard Operating Procedures
In the draft guidance, FDA
recommends that sponsors establish
procedures to do the following things:
• Assess potential conflicts of interest
of proposed DMC members;
• Ensure that those with serious
conflicts of interest are not included on
the DMC;
• Provide disclosure to all DMC
members of any potential conflicts that
are not thought to impede objectivity
and, thus, would not preclude service
on the DMC;
• Identify and disclose any
concurrent service of any DMC member
on other DMCs of the same, related or
competing products;
• Ensure separation, and designate a
different statistician to advise on the
management of the trial, if the primary
study statistician takes on the
responsibility for interim analysis and
reporting to the DMC; and
• Minimize the risks of bias that are
associated with such arrangements, if
the primary study statistician takes on
the responsibility for interim analysis
and reporting to the DMC, and it
appears infeasible or highly impractical
for any other statistician to take over
responsibilities related to trial
management.
E. Meeting Records
FDA recommends in the draft
guidance that the DMC or the group
preparing the interim reports to the
DMC maintain all meeting records. This
information should be submitted to FDA
with the clinical study report
(§ 314.50(d)(5)(ii) (21 CFR
314.50(d)(5)(ii))).
Description of Respondents: The
submission and data collection
recommendations described in this
document affect sponsors of clinical
trials and DMCs.
Burden Estimate: Table 1 of this
document provides the burden estimate
of the annual reporting burden for the
information to be submitted in
accordance with the revised draft
guidance. Table 2 of this document
provides the burden estimate of the
annual recordkeeping burden for the
information to be maintained in
accordance with the revised draft
guidance.
Based on information from FDA
review divisions, FDA estimates there
are currently 740 clinical trials with
DMCs regulated by CBER, the Center for
Drug Evaluation and Research, and the
Center for Devices and Radiological
Health. FDA estimates that the average
length of a clinical trial is 2 years,
resulting in an annual estimate of 370
clinical trials. Because FDA has no
information on which to project a
change in the use of DMCs, FDA
estimates that the number of clinical
trials with DMCs will not change
significantly in the next few years. For
purposes of this information collection,
FDA estimates that each sponsor is
responsible for approximately 10 trials,
resulting in an estimated 37 sponsors
affected by the guidance annually.
Based on information provided to
FDA by sponsors that have typically
used DMCs for the kinds of studies for
which this draft guidance recommends
them, FDA estimates that the majority of
sponsors have already prepared SOPs
for DMCs, and only a minimum amount
of time would be necessary to revise or
update them for use for other clinical
studies. FDA receives very few requests
for waivers regarding expedited
reporting of certain serious events,
therefore, FDA has estimated one
respondent per year to account for the
rare instance a request may be made.
FDA estimates that the DMCs would
hold two meetings per year per clinical
trial resulting in the issuance of two
DMC reports of the meeting minutes to
the sponsor. One set of both of the
meeting records should be maintained
per clinical trial.
The ‘‘Hours per Response’’ and
‘‘Hours per Record’’ are based on FDA’s
experience with comparable
recordkeeping and reporting provisions
applicable to FDA regulated industry.
The ‘‘Hours per Response’’ include the
time the respondent would spend
reviewing, gathering, and preparing the
information to be submitted to the DMC,
FDA, or the sponsor. The ‘‘Hours per
Record’’ include the time to record,
gather, and maintain the information.
In the Federal Register of November
20, 2001 (FR 66 58151), FDA published
a 60-day notice requesting public
comment on the information collection
provisions in the draft guidance. FDA
received a number of comments on the
draft guidance, however, only one letter
of comment included comments
regarding the information collection
provisions.
The comment stated that the ‘‘Hours
per Response’’ were underestimated for
the SOPs and Data Analysis Plan
(statistical approach) listed in table 1 of
the 60-day notice (66 FR 58151 at
58153) for the ‘‘Estimated Annual
Reporting Burden.’’ The comment
requested an increase to 12 hours for
these burdens from the previous
estimate of 4 hours for the SOPs, and 8
hours for the Data Analysis Plan.
In revising the draft guidance, FDA is
adding the applicable regulations
throughout the draft guidance including
the regulations associated with these
two burden estimates. The burden
associated with the submission of SOPs
and the statistical approach in table 1 of
the 60-day notice is covered under
§§ 312.23 and 812.150(b)(10) and is
approved under OMB Control Nos.
0910–0014 and 0910–0078. Therefore,
these categories were removed from
table 1 and no change in the burden
estimates is necessary.
Based on revisions to the draft
guidance, however, two additional
information collection burdens have
been added to table 1 of this document,
and one additional previous information
collection burden was deleted from
table 1 of the 60-day notice.
The information collection provisions
in the draft guidance for §§ 312.30,
312.32, 312.38, 312.55, and 312.56 have
been approved under OMB Control No.
0910–0014; § 314.50 has been approved
under OMB Control No. 0910–0001; and
§§ 812.35 and 812.150 have been
approved under OMB Control No. 0190–
0078.
The total estimated burden for both
the reporting and recordkeeping
burdens under the draft guidance are
1,794.75 hours.
wwhite on PROD1PC61 with NOTICES
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
Section of Draft Guidance/
Reporting Activity
No. of
Respondents
4.4.1.2 Sponsor notification to the
DMC regarding waivers of expedited
reporting
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
Annual Frequency
per Response
1
PO 00000
Frm 00033
Total Annual
Responses
1
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
Hours per
Response
1
Total Hours
.25
30DEN1
.25
77405
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
Section of Draft Guidance/
Reporting Activity
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
4.4.3.2 DMC reports of meeting minutes to the sponsor
370
2
740
1
740
5 Sponsor reporting to FDA on DMC
safety-related recommendations
37
1
37
.5
18.5
Total
1 There
758.75
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
Reporting Activity
Annual Frequency
per Recordkeeping
Total Annual
Records
Hours per
Record
Total Hours
4.1 and 6.4 SOPs for DMCs
37
1
37
8
296
4.4.3.2 DMC meeting records
370
1
370
2
740
Total
1 There
1,036
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5–8115 Filed 12–29–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Privacy Act System of Records
AGENCY:
Indian Health Service (IHS),
HHS.
Amendment of one altered
Privacy Act system of records.
ACTION:
SUMMARY: Pursuant to the provisions of
the Privacy Act of 1974, as amended, 5
U.S.C. 552a(e)(4), the IHS has amended
and is publishing the proposed
alteration of a system of records, System
No. 09–17–0001, ‘‘Medical, Health and
Billing Records.’’ The amended and
altered system of records makes only
administrative edits and revisions as
necessary.
The amended and altered
system, which incorporates the
comments received following the initial
publication, shall become effective
December 30, 2005.
FOR FURTHER INFORMATION: Contact Ms.
Patricia Gowan, IHS Lead Health
Information Management (HIM)
Consultant (Acting), Office of Health
Programs, Phoenix Area Office IHS,
Two Renaissance Square, Suite 606, 40
North Central Avenue, Phoenix, AZ
85004 or via the Internet at
Patricia.Gowan@ihs.gov.
wwhite on PROD1PC61 with NOTICES
DATES:
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
As
required by the Privacy Act of 1974, as
amended, 5 U.S.C. 552a(e)(4), this
document sets forth the amendment of
the proposed alteration of a system of
records maintained by the IHS, in
response to comments received
following the initial publication in the
Federal Register at 70 FR 49931 on
August 25, 2005. The purpose of
altering System No. 09–17–0001,
‘‘Health and Medical Records,’’ is to
enable the IHS to clarify that IHS also
uses the records in the system to
process, document, and monitor thirdparty payment billing and
reimbursement claims, in addition to
debt collection activities; to include
contract health service records; to
include several new and modified
purposes and new and modified routine
uses that are in line with the Health
Insurance Portability and
Accountability Act (HIPAA) Privacy
Rule provisions and Agency policy
changes. IHS published the notification
of the altered Privacy Act system of
records in the Federal Register on
August 25, 2005. During the comment
period, IHS received several responses
from the public. After a careful review
of their concerns, IHS does not agree
with the suggested changes and
therefore has not revised the notice. One
of the commentors suggested revising
routine use #10 so that it would provide
an exception that would enable IHS to
disclose patient health information for
public health purposes. IHS has decided
not to accept the recommendation of
this comment because the IHS already
complies with state laws that
specifically require disclosures of health
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
information for public health activities
under the current routine use #7. In
addition, the proposed routine use #10
modifies and replaces the current
routine use #7 to allow disclosures ‘‘as
authorized by law’’ which is a broader
standard than the current ‘‘as required
by law’’ standard. In fact, the particular
example submitted by the commentor in
support of the recommendation does not
meet the public health authority and
activities criteria of the HIPAA Privacy
Rule. The Nevada State Pharmacy Board
is not a public health authority and
reporting such information to a state
database appears to be primarily for law
enforcement purposes. The Nevada
statute also does not specifically require
IHS or other Federal agencies to report
to their database.
Another comment stated that ‘‘IHS
consider changing the permissive word
‘‘may’’ to the mandatory word ‘‘shall’’ in
regards to the proposed Routine Use
Number 23.’’ In response to the
comment, IHS has decided to reject the
comment based on the fact that routine
use disclosures are not mandatory but
are discretionary disclosures made by
the appropriate IHS Privacy Act System
Manager for which is defined in the
Privacy Act of 1974, as amended, 5
U.S.C. 552a; and the OMB Privacy Act
Implementation Guidelines and
Responsibilities of July 9, 1975.
The revision or modification of
various IHS and Federal Records
addresses in Appendix 1 and Appendix
2 is necessary to this system of records
as administrative edits or changes. In
Appendix 1, the address for the Fort
McDermitt Clinic under the Phoenix
Area IHS was inadvertently omitted;
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 70, Number 250 (Friday, December 30, 2005)]
[Notices]
[Pages 77403-77405]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-8115]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2001D-0489] (formerly Docket No. 01D-0489)
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Draft Guidance for
Clinical Trial Sponsors: Establishment and Operation of Clinical Trial
Data Monitoring Committees
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by January
30, 2005.
ADDRESSES: OMB is still experiencing significant delays in the regular
mail, including first class and express mail, and messenger deliveries
are not being accepted. To ensure that comments on the information
collection are received, OMB recommends that written comments be faxed
to the Office of Information and Regulatory Affairs, OMB, Attn: Fumie
Yokota, Desk Officer for FDA, FAX: 202-395-6974.
Submit written requests for single copies of the draft guidance
dated December 2005 to the Office of Communication, Training, and
Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and
Research (CBER), Food and Drug Administration, 1401 Rockville Pike,
Rockville, MD 20852-1448. Send one self-addressed adhesive label to
assist the office in processing your requests. The draft guidance may
also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-
1800. Persons with access to the Internet may obtain the draft guidance
at either https://www.fda.gov/cber/guidelines.htm or https://www.fda.gov/
ohrms/dockets/default.htm.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-4659.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Draft Guidance for Clinical Trial Sponsors: Establishment and Operation
of Clinical Trial Data Monitoring Committees
The draft guidance document, when finalized, is intended to assist
sponsors of clinical trials in determining when a Data Monitoring
Committee (DMC) is needed for study monitoring, and how such committees
should operate. The draft guidance was revised based on public
comments. The draft guidance addresses the roles, responsibilities, and
operating procedures of DMCs, and describes certain reporting and
recordkeeping responsibilities including the following: (1) Sponsor
notification to the DMC regarding waivers of expedited reporting, (2)
DMC reports of meeting minutes to the sponsor, (3) sponsor reporting to
FDA on DMC safety-related recommendations, (4) standard operating
procedures (SOPs) for DMCs, (5) DMC meeting records, and (6) DMC
reports to the sponsor.
A. Sponsor Notification to the DMC Regarding Waivers
The sponsor has the responsibility of reporting to FDA serious,
unexpected adverse events in drugs and biologics trials under part 312
(21 CFR part 312) in Sec. 312.32 and unanticipated adverse events in
the case of device trials under part 812 (21 CFR part 812) in Sec.
812.150(b)(1). We recommend in the draft guidance that sponsors notify
DMCs about any waivers granted by FDA for expedited reporting of
certain serious events.
B. DMC Report of Meeting Minutes to the Sponsor
FDA recommends in the draft guidance that the DMC issue a written
report to the sponsor based on the meeting minutes. Reports to the
sponsor should include only those data generally available to the
sponsor. The sponsor may convey the relevant information in this report
to other interested parties such as study investigators. Meeting
minutes or other information that include discussion of confidential
data would not be provided to the sponsor.
C. Sponsor reporting to FDA on DMC Safety-Related Recommendations
The requirement of the sponsor to report DMC recommendations
related to serious adverse events in an expedited manner in clinical
trials of new drugs (Sec. 312.32(c)) would not apply when the DMC
recommendation is related to an excess of events not classifiable as
[[Page 77404]]
serious. Nevertheless, we recommend in the draft guidance that sponsors
inform FDA about all recommendations related to the safety of the
investigational product whether or not the adverse event in question
meets the definition of ``serious.''
D. Standard Operating Procedures
In the draft guidance, FDA recommends that sponsors establish
procedures to do the following things:
Assess potential conflicts of interest of proposed DMC
members;
Ensure that those with serious conflicts of interest are
not included on the DMC;
Provide disclosure to all DMC members of any potential
conflicts that are not thought to impede objectivity and, thus, would
not preclude service on the DMC;
Identify and disclose any concurrent service of any DMC
member on other DMCs of the same, related or competing products;
Ensure separation, and designate a different statistician
to advise on the management of the trial, if the primary study
statistician takes on the responsibility for interim analysis and
reporting to the DMC; and
Minimize the risks of bias that are associated with such
arrangements, if the primary study statistician takes on the
responsibility for interim analysis and reporting to the DMC, and it
appears infeasible or highly impractical for any other statistician to
take over responsibilities related to trial management.
E. Meeting Records
FDA recommends in the draft guidance that the DMC or the group
preparing the interim reports to the DMC maintain all meeting records.
This information should be submitted to FDA with the clinical study
report (Sec. 314.50(d)(5)(ii) (21 CFR 314.50(d)(5)(ii))).
Description of Respondents: The submission and data collection
recommendations described in this document affect sponsors of clinical
trials and DMCs.
Burden Estimate: Table 1 of this document provides the burden
estimate of the annual reporting burden for the information to be
submitted in accordance with the revised draft guidance. Table 2 of
this document provides the burden estimate of the annual recordkeeping
burden for the information to be maintained in accordance with the
revised draft guidance.
Based on information from FDA review divisions, FDA estimates there
are currently 740 clinical trials with DMCs regulated by CBER, the
Center for Drug Evaluation and Research, and the Center for Devices and
Radiological Health. FDA estimates that the average length of a
clinical trial is 2 years, resulting in an annual estimate of 370
clinical trials. Because FDA has no information on which to project a
change in the use of DMCs, FDA estimates that the number of clinical
trials with DMCs will not change significantly in the next few years.
For purposes of this information collection, FDA estimates that each
sponsor is responsible for approximately 10 trials, resulting in an
estimated 37 sponsors affected by the guidance annually.
Based on information provided to FDA by sponsors that have
typically used DMCs for the kinds of studies for which this draft
guidance recommends them, FDA estimates that the majority of sponsors
have already prepared SOPs for DMCs, and only a minimum amount of time
would be necessary to revise or update them for use for other clinical
studies. FDA receives very few requests for waivers regarding expedited
reporting of certain serious events, therefore, FDA has estimated one
respondent per year to account for the rare instance a request may be
made. FDA estimates that the DMCs would hold two meetings per year per
clinical trial resulting in the issuance of two DMC reports of the
meeting minutes to the sponsor. One set of both of the meeting records
should be maintained per clinical trial.
The ``Hours per Response'' and ``Hours per Record'' are based on
FDA's experience with comparable recordkeeping and reporting provisions
applicable to FDA regulated industry. The ``Hours per Response''
include the time the respondent would spend reviewing, gathering, and
preparing the information to be submitted to the DMC, FDA, or the
sponsor. The ``Hours per Record'' include the time to record, gather,
and maintain the information.
In the Federal Register of November 20, 2001 (FR 66 58151), FDA
published a 60-day notice requesting public comment on the information
collection provisions in the draft guidance. FDA received a number of
comments on the draft guidance, however, only one letter of comment
included comments regarding the information collection provisions.
The comment stated that the ``Hours per Response'' were
underestimated for the SOPs and Data Analysis Plan (statistical
approach) listed in table 1 of the 60-day notice (66 FR 58151 at 58153)
for the ``Estimated Annual Reporting Burden.'' The comment requested an
increase to 12 hours for these burdens from the previous estimate of 4
hours for the SOPs, and 8 hours for the Data Analysis Plan.
In revising the draft guidance, FDA is adding the applicable
regulations throughout the draft guidance including the regulations
associated with these two burden estimates. The burden associated with
the submission of SOPs and the statistical approach in table 1 of the
60-day notice is covered under Sec. Sec. 312.23 and 812.150(b)(10) and
is approved under OMB Control Nos. 0910-0014 and 0910-0078. Therefore,
these categories were removed from table 1 and no change in the burden
estimates is necessary.
Based on revisions to the draft guidance, however, two additional
information collection burdens have been added to table 1 of this
document, and one additional previous information collection burden was
deleted from table 1 of the 60-day notice.
The information collection provisions in the draft guidance for
Sec. Sec. 312.30, 312.32, 312.38, 312.55, and 312.56 have been
approved under OMB Control No. 0910-0014; Sec. 314.50 has been
approved under OMB Control No. 0910-0001; and Sec. Sec. 812.35 and
812.150 have been approved under OMB Control No. 0190-0078.
The total estimated burden for both the reporting and recordkeeping
burdens under the draft guidance are 1,794.75 hours.
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Section of Draft
Guidance/ No. of Annual Frequency Total Annual Hours per
Reporting Respondents per Response Responses Response Total Hours
Activity
----------------------------------------------------------------------------------------------------------------
4.4.1.2 Sponsor 1 1 1 .25 .25
notification to
the DMC
regarding
waivers of
expedited
reporting
-----------------
[[Page 77405]]
-----------------
-------------------------------------
Total 758.75
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Reporting No. of Annual Frequency Total Annual
Activity Recordkeepers per Recordkeeping Records Hours per Record Total Hours
----------------------------------------------------------------------------------------------------------------
4.1 and 6.4 37 1 37 8 296
SOPs for DMCs
---------------====================
-----------------------------------
Total 1,036
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: December 22, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E5-8115 Filed 12-29-05; 8:45 am]
BILLING CODE 4160-01-S
